A5053667290- Virus-based gene therapy research
- Veterinary Oncology Research
- Immunotherapy and Immune Responses
- Viral gastroenteritis research and epidemiology
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cell Adhesion Molecules Research
- Cancer Research and Treatments
- Infectious Diseases and Mycology
- Animal Virus Infections Studies
- Gastrointestinal Tumor Research and Treatment
- RNA Interference and Gene Delivery
- Monoclonal and Polyclonal Antibodies Research
- Genomics, phytochemicals, and oxidative stress
- Platelet Disorders and Treatments
- Fibroblast Growth Factor Research
- Sarcoma Diagnosis and Treatment
- Blood Coagulation and Thrombosis Mechanisms
- Heme Oxygenase-1 and Carbon Monoxide
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer-related Molecular Pathways
- Cancer, Hypoxia, and Metabolism
- Radiation Therapy and Dosimetry
Yamaguchi University
2015-2025
Japan Small Animal Medical Center
2025
Abstract Inhibition of programmed death 1 (PD-1), expressed on activated T cells, can break through immune resistance and elicit durable responses in human melanoma as well other types cancers. Canine oral malignant is one the most aggressive tumors bearing poor prognosis due to its high metastatic potency. However, there are few effective treatments for advanced stages veterinary medicine. Only previous study indicated potential checkpoint inhibitor, anti-canine PD-L1 therapeutic antibody...
The anti-programmed death 1 (PD-1) antibody has led to durable clinical responses in a wide variety of human tumors. We have previously developed the caninized anti-canine PD-1 (ca-4F12-E6) and evaluated its therapeutic properties dogs with advance-staged oral malignant melanoma (OMM), however, their effects on other types canine tumors remain unclear.
A monoclonal antibody targeting programmed cell death-1 (PD-1) is one of the most promising treatments for human cancers. Clinical studies in humans demonstrated that anti-PD-1 provides a long-lasting tumour response. Previously, we established an anti-canine PD-1 therapeutic (ca-4F12-E6), and pilot clinical study was effective dogs with oral malignant melanoma (OMM). However, two OMM cases were still undergoing treatment when published. Here, describe long-term follow-up those cases....
Abstract Lymphoma is the most common hematological cancer in dogs. Canine diffuse large B cell lymphoma shows a relatively good response to treatment with multi-agent cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy; however, 2-year survival rate as low 20%. For human type lymphoma, anti-CD20 chimeric antibody, rituximab, was developed two decades ago. The combination of rituximab CHOP chemotherapy highly successful improving patient prognosis. However, no...
Lingual canine T-zone lymphoma (TZL) is a rare form of extranodal lymphoma. 7-years and 5 months old, spayed female toy poodle presented with red swollen mass on the tongue. A punch biopsy lesion was conducted, followed by histopathological immunohistochemical analyses. Despite absence lymph node excisional biopsy, case diagnosed as lingual TZL. Although there no established treatment for TZL, often follows TZL protocols. In this case, tongue improved after administration oclacitinib, drug...
Oncolytic virotherapy is a novel treatment involving replication‐competent virus in the elimination of cancer. We have previously reported oncolytic effects reovirus various canine cancer cell lines. This study aims to establish safety profile dogs with spontaneously occurring tumours and determine recommended dosing regimen. Nineteen tumours, mostly advanced stages, were treated reovirus, ranging from 1.0 × 10 8 5.0 9 TCID 50 given as intratumour injection (IT) or intravenous infusion (IV)...
Oncolytic virotherapy is a new strategy for cancer treatment humans and dogs. Reovirus has been proven to be potent oncolytic virus in human medicine. Our laboratory previously reported that canine mast cell tumor lymphoma were susceptible reovirus. In this study, solid lines (mammary gland tumor, osteosarcoma malignant melanoma) tested determine their susceptibility towards We demonstrated reovirus induces more than 50% death three mammary tumors one melanoma line. The reovirus-induced...
Background/Aim: The activation of phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway has been implicated in canine soft tissue sarcoma (STS) and may serve as a prognostic marker. This study investigated the correlation between PI3K/Akt tumor cells tumor-infiltrating lymphocytes (TILs). Materials Methods: A total 59 STS samples were labeled via immunohistochemistry to calculate density TILs, including CD3+ T cells, CD8+ CD20+ B FOXP3+ regulatory cells. Results: Forty-eight (81.3%) had...
Reovirus is a potent oncolytic virus in many human neoplasms that has reached phase II and III clinical trials. Our laboratory previously reported the effects of reovirus canine mast cell tumour (MCT). In order to further explore potential veterinary oncology, we tested susceptibility 10 lymphoma lines. Reovirus-induced death, replication infectivity were confirmed four lines with variable levels susceptibility. The level Ras activation varied among no correlation Reovirus-susceptible...
Abstract Canine B‐cell lymphoma is one of the most common haematopoietic neoplasms in veterinary medicine, and it considered a relevant model for human diffuse large lymphoma. Although standard treatment consisting multi‐drug chemotherapy effective cases, often challenging because relapse drug resistance. The adoptive transfer autologous T cells genetically modified to express CD19‐specific chimeric antigen receptor (CD19 CAR‐T cells) has been shown be highly malignancies. However, there no...
Background SRC kinase (SRC proto‐oncogene, non‐receptor tyrosine kinase) is a promising target for the treatment of solid cancers including human melanoma. Bosutinib (Bosu), inhibitor, has already been applied to chronic myelogenous leukemia and also assessed its safety in dogs. Aim The aim this study was clarify novel anti‐tumour mechanism Bosu canine melanoma cells. Materials Methods cells were treated with effects evaluated by cell viability, protein expression levels such as caspase‐3...
Hypoxic conditions in various cancers are believed to relate with their malignancy, and hypoxia inducible factor-1α (HIF-1α) has been shown be a major regulator of the response low oxygen. In this study, we examined HIF-1α expression canine lymphoma using cell lines clinical samples found that these cells expressed HIF-1α. Moreover, inhibitors, echinomycin, YC-1 2-methoxyestradiol, suppressed proliferation lines. xenograft model NOD/scid mice, echinomycin treatment resulted dose-dependent...
Radiotherapy is one of the most effective cancer treatments. Au nanoparticles (NPs) are used X-ray sensitizing materials however small sub-nm size NPs for sensitizers disadvantageous cellular uptake. Here, we propose surface functionalization organosilica (OS) with (OS/Au), which combined 100 nm OS and NPs, synthesized as an sensitizer. The potential 4T1 mouse mammary tumor cells was revealed using a multifaceted evaluation fluorescence microscopic cell imaging assay. number...
Oncolytic virotherapy using reovirus is a promising new anti-cancer treatment with potential for use in humans and dogs. Because monotherapy shows limited efficacy human canine cancer patients, the clinical development of combination therapy necessary. To identify candidate components such combination, we screened 285-compound drug library those that enhanced cytotoxicity melanoma cell line. Here, show exposure to an inhibitor ataxia telangiectasia mutated protein (ATM) enhances oncolytic...
A 10-year-old female spayed mixed breed cat with a subcutaneous mass on the right hind limb was revealed bimodal monoclonal gammopathy composed of IgA by immunoelectrophoresis and immunofixation. Approximately 1 month after referral, died due to renal failure. Postmortem immunohistopathologic evaluation neoplastic cell proliferation plasma cells giant myeloma cells. Neoplastic were also present in liver spleen. These results led diagnosis rare case feline myeloma-related disorders...
Canine histiocytic sarcoma is an aggressive, fatal neoplastic disease with a poor prognosis. Lomustine generally accepted as the first-line systemic therapy, although this compound does not provide complete regression. Therefore, research into novel approach against canine needed. However, anti-tumour effects of oncolytic therapy using reovirus are unknown. Here, we showed that has activity in cell lines vitro and vivo. We found can replicate induce caspase-dependent apoptosis lines. A...
A 6-year-old spayed female Jack Russell Terrier presented with a 1-month history of lethargy, anorexia, vomiting and weight loss. The dog was fed beef chicken jerky treats daily in addition to commercial diet. Laboratory tests revealed azotemia, hypokalemia, hyperchloremia, metabolic acidosis glucosuria normoglycemia. Urine amino acid analysis showed significant loss into the urine. Thus, Fanconi syndrome diagnosed, based on case extensive diagnostic testing, excessive consumption strongly...